steatohepatitis
Navigation Links
steatohepatitis in Medical News
FASgen Announces New Diagnostic Research Test for Steatohepatitis
BALTIMORE, FASgen Inc. announced it has successfully expanded the potential use for its serum FAS (fatty acid synthase) ELISA diagnostic research test, FAS-Detect(TM) ELISA for the identification of Non-Alcoholic Steatohepatitis (NASH). The current diagnostic technique for this disease is ...Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
...e the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis , non-alcoholic steatohepatitis ("NASH") , Huntington's Disease ("HD") , and aldehyde dehydrogenase ("ALDH2") deficiency . Raptor's preclinical programs are based upon...Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family Conference
...e the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis , non-alcoholic steatohepatitis ("NASH") , Huntington's Disease ("HD") , and aldehyde dehydrogenase ("ALDH2") deficiency . Raptor's preclinical programs are based up...Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
...an have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), and aldehyde dehydrogenase ("ALDH2") deficiency. Raptor's preclinical programs are based upon bioengineer...Intestinal bacteria associated with non-alcoholic fatty liver disease
...sult of a high fat diet. Importantly, there was no association between either small intestinal bacterial overgrowth or intestinal permeability and steatohepatitis or fibrosis, which argues against a primary role for gut bacteria in the progression of NAFLD to more severe liver disease. "In conclusion," the au...Hyperferritinemia is another surrogate marker of advanced liver disease
... High serum ferritin, being a hallmark of hereditary hemochromatosis , is frequently found in chronic hepatitis C, alcoholic or non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients . A study in Italy has investigated the link between ferritin and steatosis in a non-obese cohort of no......lion deaths annually. The main causative agents are hepatitis B virus (HBV), hepatitis C virus (HCV), as well as alcoholic cirrhosis and non-alcoholic steatohepatitis (NASH) which is associated with obesity and diabetes. The incidence of HCC has been steadily increasing over the past ten years and is expected to con...
Is telmisartan effective in treating non-alcoholic steatohepatitis?
...olic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive l...uating the effects of telmisartan and valsartan in steatohepatitis that uses paired liver biopsies with NAS evaluatio...nsion, but also can act by preventing and treating steatohepatitis as an end-organ effect of metabolic syndrome. On t...Weight loss improves fatty liver disease, researchers find
... Saint Louis University researchers found that weight loss of at least 9 percent helped patients reverse a type of liver disease known as nonalcoholic steatohepatitis (NASH), a finding that will allow doctors to give patients specific weight-loss goals that are likely to improve their livers. The finding comes from ......nic in Cleveland, Ohio. He is also the vice chair for Research for the Division of Medicine. His research interests include the study of non-alcoholic steatohepatitis and alcoholic steatohepatitis. The major research interests of his laboratory include the study of the normal response of protein and energy metabolis...
steatohepatitis in Medical Technology
Study Evaluating Cysteamine in Collaboration with UC San Diego
NOVATO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the completion of patient enrollment in its Phase 2a open-label clinical trial t...
Commences Patient Dosing of Delayed-ReleaseCysteamine in Collaboration with UC, San Diego NOVATO, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the initiation of patient dosing in a Phase 2a clin...
...ated with the metabolic syndrome and other life threatening diseases. NAFLD is known to progress to more advanced liver diseases such as non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and liver cancer. Nanoveson(TM) is a novel approach to treating and diagnosing liver diseases and comorbid diseases u...
...t. Raptor is currently running clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human recep...
... of potential indications including Huntington's, cystinosis, non-alcoholic steatohepatitis ("NASH") and Batten Disease. Raptor is currently collaborating with UCSD in...hydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor's preclinical programs are based upon bioengineered novel ...
Commences Patient Dosing of Delayed-ReleaseCysteamine in Collaboration with UC, San Diego NOVATO, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the initiation of patient dosing in a Phase 2a clin...
...ated with the metabolic syndrome and other life threatening diseases. NAFLD is known to progress to more advanced liver diseases such as non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and liver cancer. Nanoveson(TM) is a novel approach to treating and diagnosing liver diseases and comorbid diseases u...
Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
...an have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("Huntington's"), and aldehyde dehydrogenase ("ALDH2") deficiency. Raptor's preclinical programs are based upon b...Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
...otential treatment of nephropathic cystinosis ("cystinosis"), non-alcoholic steatohepatitis ("NASH") and Huntington's Disease ("Huntington's"), as well as Convivia(TM)...tes in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("Huntington's"), and aldehyde dehydrogenase......t. Raptor is currently running clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human recep...
... of potential indications including Huntington's, cystinosis, non-alcoholic steatohepatitis ("NASH") and Batten Disease. Raptor is currently collaborating with UCSD in...hydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor's preclinical programs are based upon bioengineered novel ...
Raptor Pharmaceuticals Provides Update on Targeting Platforms
...e Company is currently running clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human recepto...Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
... Phase 2a clinical trial to evaluate a delayed-release preparation of cysteamine bitartrate ("Cysteamine") in adolescents diagnosed with Non-Alcoholic steatohepatitis ("NASH"). NASH is a progressive form of liver disease that accounts for approximately 10% of newly diagnosed cases of chronic liver disease, and ranks...NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease
...ean Association for the Study of the Liver (EASL) further confirm that nonalcoholic fatty liver disease (NAFLD) and its most severe form, nonalcoholic steatohepatitis (NASH), are associated with the metabolic syndrome and pose an increased risk of cardiovascular disease. NAFLD and NASH are significant health probl...steatohepatitis in Medical Dictionary
..... ... ranging from simple fatty liver (steatosis), to nonalcoholic steatohepatitis ... What are Fatty Liver , NAFLD, and NASH? What is the NAFLD spectrum? ...llect ... NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NONALCOHOLIC steatohepatitis (NASH) ... It consists of two stages – a fatty liver and NASH (nonalcoh...
steatohepatitis in Biological News
Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis
...oncerning diagnosis and prognosis of non-alcoholic steatohepatitis (NASH), allowing the discrimination between normal...sis and NASH predisposed subjects. Non alcoholic steatohepatitis is a progressive disease of the liver of unknown e...his chip also assess the efficacy of non-alcoholic steatohepatitis treatment by determining progression or regression...steatohepatitis in Biological Technology
Research to be presented Sunday, November 2, 2008 at this year's liver meeting in San Francisco, California, October 31 - November 4
SAN FRANCISCO, Oct. 27 /PRNewswire/ -- Nonalcoholic steatohepatitis
(NASH) is strongly associated with obesity, and there is no approved
medical therapy for...
... for use of cysteamine and DR Cysteamine for the treatment of non-alcoholic steatohepatitis ("NASH"), a progressive liver disease believed to affect 2-5% of the U.S. p...tes in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), and aldehyde dehydrogenase ("ALDH2")...
... for use of cysteamine and DR Cysteamine for the treatment of non-alcoholic steatohepatitis ("NASH"), a progressive liver disease believed to affect 2-5% of the U.S. p...tes in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), and aldehyde dehydrogenase ("ALDH2")...
Obio Pharmaceutical Announces Product Growth Strategy
...Diabetes II, has been granted patents in USA and South Africa. The Company has also successfully patented the AK20 in China, which treats Nonalcoholic steatohepatitis (NASH/ nonalcoholic fatty liver disease). Besides the two patented drugs, Obio has also discovered an antiviral drug candidate -- TG21 that cou...Raptor Pharmaceuticals Closes $10 Million Private Placement
...on. Raptor's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor preclinical programs target cancer, neurodegenerative disorders and infectious diseases. HepTide(TM) is designed to utilize enginee...Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
...on. Raptor's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor preclinical programs target cancer, neurodegenerative disorders and infectious diseases. HepTide(TM) is designed to utilize enginee...Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
...ty of California, San Diego ("UCSD") around the use of Cysteamine, and Delayed Release Cysteamine ("DR Cysteamine") for the treatment of Non-alcoholic steatohepatitis ("NASH"). In collaboration with doctors from UCSD School of Medicine, Bennu plans to initiate a Phase 2a clinical study of DR Cysteamine in NASH patie...steatohepatitis in Biological Dictionary
...onal organization representing physicians who treat ... Describes the liver diseases steatosis, hepatitis, and cirrhosis, as well ... Liver ... steatohepatitis is fatty liver accompanied by inflammation and ... Liver , largest internal organ of the human body. ... Liver - Wikipedia, the free encyc...
Other TagsCarbonCarbonCarbonCanineLiquidLiquidLiquidMinimalLiverLiverLiverLiverLiverLiverLiverOther Contentsforebrainforebrainforebrainfossilfossilfossilfossilfossilfrondframeshiftfungifungifungifungifungifungifructosefructosefructosefructosefructosefusionfusionfusionfusionfusionfusionfusionfusionfusion
UltrasoundsGuidingFeinsteinCarbonUnderdogsCanineLiquidMinimalSweetgumIntelligentlyLiverRochesterWyomingScaled
(Date:12/1/2009).... 1 The Kerlan Jobe Ort...ngeles, has agreed to pay the United States $3 mil...l kickbacks from HealthSouth Corporation, the Just...tlement resolves allegations that HealthSouth paid...ion grants, donations to the Kerlan Jobe Foundatio...
(Date:12/1/2009)...ec. 1 A decision issued today by a... Board (NLRB) has put at risk the guaranteed raise...manente RNs, social workers, and professionals in ...rs to achieve standards at Kaiser that give us sec...e our patients need," said Jeanette Cryer, License...
(Date:12/1/2009)...gests that criteria based on computed tomography (...iver metastases after chemotherapy with the drug b...ll survival, according to a study in the December ...b to cytotoxic (toxic to cells) chemotherapy is as...tage IV colorectal cancer and higher pathologic re...
(Date:12/1/2009)...NS, Dec. 1 The American...High School Student Symposium at the New Orleans M... The symposium, which encourages an interest in he...earch, is held in conjunction with the Society,s 5...the opportunity to explore research on sickle cell...
(Date:12/1/2009)...Dec. 1 The government of Mexico Ci...ter for biomedical and nanomedical research, calle...search and development will be integrated with the... Spanish speaking university in the world. The re... 2010, has been designed by the internationally-ac...
Breaking Medicine News(10 mins):Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2Health News:Labor Board Decision Puts Kaiser Workers' Pay, Healthcare, Pensions in Jeopardy 2Health News:Criteria based on CT imaging after chemotherapy may help predict survival 2Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 2Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 3Health News:Mexico City to Build World-Class Hub for Medical Research 2[0] Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations[0] Labor Board Decision Puts Kaiser Workers' Pay, Healthcare, Pensions in Jeopardy[0] Criteria based on CT imaging after chemotherapy may help predict survival[1] ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum[1] Mexico City to Build World-Class Hub for Medical Research
(Date:12/1/2009)...NNYVALE, Calif., Dec. 1 GestureTek...ase 3.0 - a turnkey, portable, plug and play inter...exhibits, entertainment and touring promotions. Ge...atents in camera-enabled gesture recognition techn...tertainment systems. ,, Guaranteed for quality,...
(Date:12/1/2009)..., winner of the 2009 Inserm Grand Prix., Every y... to paying tribute to outstanding,work performed ...talents, Inserm intends to,demonstrate the divers...iological, medical and,health research, and the c...ry out and,drive this research each day. The Inse...
(Date:12/1/2009)...sh. -- Time-lapsed video of individual breast tiss...life of a cell: a protein that cycles between two ...esearchers a more complete view of the internal si...ts that go awry in cancer and are targets of drug ...ls respond to growth factors, travels back and for...
Breaking Biology News(10 mins):GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 2ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 3ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 4Expanding into New Markets with Customer Focused Solutions Orion Health Sees Strong Growth 50233 1Expanding into New Markets with Customer Focused Solutions Orion Health Sees Strong Growth 50233 2Expanding into New Markets with Customer Focused Solutions Orion Health Sees Strong Growth 50233 3Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 4661 1Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 4661 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 4661 3Mice run faster on high grade oil 9038 1Mice run faster on high grade oil 9038 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |